MESC Stock Overview
Through its subsidiaries, engages in the cultivation and research of peyote cactus. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Lophos Holdings Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.01 |
| 52 Week High | CA$0.14 |
| 52 Week Low | CA$0.01 |
| Beta | 0 |
| 11 Month Change | 0% |
| 3 Month Change | -33.33% |
| 1 Year Change | -71.43% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -93.55% |
Recent News & Updates
Shareholder Returns
| MESC | CA Pharmaceuticals | CA Market | |
|---|---|---|---|
| 7D | 0% | 10.1% | 0.2% |
| 1Y | -71.4% | -19.0% | 21.0% |
Return vs Industry: MESC underperformed the Canadian Pharmaceuticals industry which returned -19% over the past year.
Return vs Market: MESC underperformed the Canadian Market which returned 21% over the past year.
Price Volatility
| MESC volatility | |
|---|---|
| MESC Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 11.8% |
| Market Average Movement | 8.3% |
| 10% most volatile stocks in CA Market | 17.5% |
| 10% least volatile stocks in CA Market | 2.9% |
Stable Share Price: MESC's share price has been volatile over the past 3 months compared to the Canadian market.
Volatility Over Time: Insufficient data to determine MESC's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Jacqueline Lupo | lophos.com |
Lophos Holdings Inc., through its subsidiaries, engages in the cultivation and research of peyote cactus. It also researches and sells compounds within the peyote cactus, including mescaline for drug development. The company is headquartered in Vancouver, Canada.
Lophos Holdings Inc. Fundamentals Summary
| MESC fundamental statistics | |
|---|---|
| Market cap | CA$858.60k |
| Earnings (TTM) | -CA$1.19m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.7x
P/E RatioIs MESC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MESC income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$1.19m |
| Earnings | -CA$1.19m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.014 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 140.6% |
How did MESC perform over the long term?
See historical performance and comparison